Best Practices for Referring Patients for CAR T Therapy

Opinion
Video

Panelists discuss the growing importance of early integration and collaboration between community oncologists and specialized centers in the evolving chimeric antigen receptor (CAR) T-cell therapy landscape for multiple myeloma, emphasizing timely referrals, coordinated care, and strategic sequencing with other immunotherapies to optimize patient outcomes.

As CAR T-cell therapy continues to evolve, it’s becoming clear that early integration into the myeloma treatment landscape will be essential. With growing experience, toxicities are being better managed, and the therapy is becoming more accessible. Community oncologists will increasingly encounter patients either undergoing or returning from CAR T treatment, making strong collaboration with specialized centers vital. Early referrals are crucial—not just for eligibility assessment but also to prepare patients and optimize access to this potentially transformative therapy before multiple relapses complicate their course.

The promise of CAR T lies not only in its deep responses but also in the durability of those responses, with emerging long-term data sparking discussions around functional cures in a subset of patients. Yet, CAR T isn’t a stand-alone solution; it will often be used in sequence with bispecifics and other immunotherapies. The key is not to choose one over the other but to work toward selecting the right therapy at the right time. Community clinicians, by collaborating with myeloma specialists, play a critical role in ensuring patients are considered for advanced treatments early and receive individualized, up-to-date care.

As the treatment landscape becomes more complex and fast moving, community providers don’t need to have all the answers—but they do need strong connections with academic centers. Even though myeloma remains a rare disease, the pace of change is rapid, and guidance from specialized teams is invaluable. By working together—academic and community providers alike—we can ensure each patient receives the most effective and timely therapy, grounded in current evidence and tailored to their specific clinical needs.

Recent Videos
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Although pembrolizumab addressed a long-standing need in adjuvant kidney cancer treatment, combinations with the agent may further bolster efficacy.
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
4 experts in this video
4 experts in this video
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
Related Content